# Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

> **NCT01371565** · PHASE3 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Cushing's Disease
- Cushing's Syndrome

## Interventions

- **DRUG:** Mifepristone

## Key facts

- **NCT ID:** NCT01371565
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-06
- **Final completion:** 2012-09
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371565, "Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01371565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*